Special Issue

Metabolomics Meets Neuropsychiatry

Message from the Guest Editors

Neuropsychiatric disorders (NPDs) such as schizophrenia, depression, bipolar, anxiety, substance abuse, attention deficit hyperactivity disorder, etc. have complex pathophysiology limiting the understanding of pathomechanisms and the discovery of novel biomarkers and therapeutic alternatives.

This Special Issue, "Metabolomics Meets
Neuropsychiatry," will highlight the implications of
targeted/untargeted metabolomic approaches in
understanding the mechanisms behind NPDs, as well as
the therapeutic and adverse effects of drugs and
identifying novel biomarkers. We invite the submission
of original research and review articles covering this
area of research, as well as studies investigating the
effects of pharmacological interventions on altering the
metabolites (neurotransmitters, lipids, amino acids, etc.)
in NPDs and associated metabolic disorders.
Furthermore, studies investigating the desired/adverse
effects of drugs and drug metabolites in treating NPDs

Guest Editors

Dr. Anurag Kuhad

Pharmacology Division, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh 160014, India


Dr. Raghunath Singh

Schizophrenia Division, Centre for Addiction and Mental Health, Toronto. ON M6J 1H4. Canada

Deadline for manuscript submissions

are also encouraged for submission.

closed (15 December 2023)



an Open Access Journal by MDPI

Impact Factor 3.7 CiteScore 6.9 Indexed in PubMed



mdpi.com/si/137810

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

mdpi.com/journal/ metabolites





Metabolites

an Open Access Journal by MDPI

Impact Factor 3.7 CiteScore 6.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo

Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.4 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the first half of 2025).

